Revenio Group stock
Price history
−59.28% over the period1 year: from €22.20 (November 20, 2025) to €9.04 (November 20, 2026), −59.28%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €9.04 |
| October 30, 2026 | €10.38 |
| September 30, 2026 | €10.68 |
| August 31, 2026 | €14.94 |
| July 31, 2026 | €12.22 |
| June 30, 2026 | €12.20 |
| May 29, 2026 | €13.96 |
| April 30, 2026 | €13.90 |
| March 31, 2026 | €18.96 |
| February 27, 2026 | €18.60 |
| January 30, 2026 | €20.05 |
| December 30, 2025 | €22.40 |
| November 28, 2025 | €22.30 |
| November 20, 2025 | €22.20 |
At a glance
The company
Develops ophthalmological devices and software for diagnosing glaucoma, macular degeneration, and diabetic retinopathy
Latest results
Quarter to September 30, 2026 · EPS €0.15 (estimate €0.08)
Next event
TickerLandia's take on Revenio Group
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 14 vs a median of 41 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 25 vs 29 (−13%) in a group of 10.
- Strong point: Earnings stability (52/100 in its group). Weak point: Market momentum (2/100).
- “Below historical valuation” (Finland): No. 1 of 3.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−61.37% from the 52-week high
Analysts · 4 analysts
Average target€11.68+29.15% vs. price
Buy 3 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Revenio Group
Compared with similar companies: very weak momentum and very high risk.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage40
How much it costs relative to what it produces.
Metric Value Position in group Price/book 2.15 8 Forward P/E 14.8 22 EV/EBITDA 25.4 85 Price/sales 3.14 53 P/E (trailing 12 months) 25.1 33 Profitabilitylow38
How much it earns on revenue and capital.
Metric Value Position in group ROE 10.3% 34 ROA 3.6% 8 Gross margin 67.9% 63 Operating margin 14.1% 31 Net margin 10.5% 56 Earnings stabilityaverage52
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.9% 47 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthaverage46
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +49.80% 95 Earnings growth (year over year) −82.80% 11 Average revenue growth (3 years) +4.15% 31 Financial strengthlow40
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.54 82 Debt/equitycounts in reverse: lower means more financial strength 1.73 5 Current ratio 0.58 2 Interest coverage 65.5 72 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak2
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −59.28% 1 Distance from 200-day average −35.18% 2 Riskvery high98
How much the price swings.
Metric Value Position in group Volatility (60 days) 71.5% 98 Maximum drawdown (12 months) 61.0% 98
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Revenio Group is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Revenio Group's P/E today is 13.8, below the median of its last 10 fiscal years (41.5; between 34.2 and 100.2 from 2016 to 2025). Revenio Group's P/E (trailing 12 months): 25.1, −13% against the median of a group of 10 similar companies (28.9).
Compared with 10 similar companies
| Metric | Revenio Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 25.1 | Low | |
| Forward P/E | 14.8 | Low | |
| Operating margin | 14.1% | Middle | |
| ROE | 10.3% | Middle | |
| Debt/equity | 1.73 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Revenio Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€59M
Latest quarter · Q3 2026
Net income
€3.4M
Latest quarter · Q3 2026
Quarterly net margin
5.8%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €390.23M
- P/E
- 25.1
- EPS
- €0.37
- Volume
- 201.83K
- Daily trading
- €960.99K
How Revenio Group is changing
All resultsRevenue grew 12.4% a year on average over the last 5 years
Operating margin fell from 30.5% to 23.1%
Profits turn into cash: free cash flow equal to 113% of net income
Returns
Revenio Group returns with dividends
€1,000 invested in Revenio Group 5 years ago, on November 22, 2021, would be worth €169 today with dividends reinvested: −83.11% in total, −29.96% per year. On price alone it would be €161 (−83.91%).
| Period | Revenio Group | €1,000 becomes |
|---|---|---|
| 1 month | −18.26% | €817 |
| 6 months | −35.70% | €643 |
| Year to date | −59.64% | €404 |
| 1 year | −59.28% | €407 |
| 3 years | −60.80% | €392 |
| 5 years | −83.11% | €169 |
| 10 years | +23.99% | €1,240 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Revenio Group: technical analysis
Revenio Group is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 87.2% below its all-time closing high (€70.70, August 4, 2021).
- Trend
- Downward
- RSI (14 sessions)
- 32
- Between 30 and 70
- vs 200-session average
- −35.18%
Support and resistance
Price areas where Revenio Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€13.35+47.71%3 touches, last on May 13, 2026
- Resistance€11.91+31.78%3 touches, last on October 14, 2026
- Resistance€10.29+13.83%2 touches, last on October 27, 2026
- Last price€9.04
- No support below: the price is near the lows of the year
Volatility and risk
- Volatility (60 sessions, annualised)
- 71.5%
- Largest fall in the last year
- −61.04%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Revenio Group: seasonality
Average monthly price change over 25 years
Over the last 25 years, the strongest month for Revenio Group has been January: +4.35% on average, positive in 13 years out of 25. The weakest has been September: −2.79% on average, positive in 9 years out of 25. November, the current month, has been positive in 14 years out of 25 (+4.19% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.35% | +2.78% | 13 of 25 |
| February | +1.32% | 0.00% | 11 of 25 |
| March | +1.25% | +0.39% | 13 of 25 |
| April | +2.29% | +2.75% | 13 of 25 |
| May | +3.42% | −1.88% | 11 of 25 |
| June | −0.74% | 0.00% | 11 of 25 |
| July | +2.48% | +1.45% | 15 of 25 |
| August | −0.15% | −3.12% | 9 of 25 |
| September | −2.79% | −0.64% | 9 of 25 |
| October | +0.53% | 0.00% | 11 of 25 |
| November | +4.19% | +3.70% | 14 of 25 |
| December | +1.42% | 0.00% | 10 of 25 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Revenio Group and its competitors
The iCare tonometer range, including the iCare HOME2 for measuring eye pressure at home and the TONOVET models used in surgical settings and by veterinarians, forms the core of the product line of Revenio Group Oyj. Alongside these devices the company sells imaging equipment such as iCare EIDON and iCare COMPASS, and software including iCare ILLUME, which uses artificial intelligence to screen for early signs of eye disease, iCare CLINIC for long-term pressure records, and the Oculo platform for telehealth and remote patient monitoring.
- Headquarters
- Vantaa, Finland
- Employees
- 765
- Founded
- 2001
- Chief executive
- Jouni Toijala
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Revenio GroupREG1V | $428.87M | 14.1% | 25.1 | −35.70% |
| Synektik Spólka AkcyjnaSNT | $647.15M | 23.3% | 15.9 | +9.15% |
| El.En.ELN | $1.44B | 14.7% | 20.7 | +10.78% |
| ChemoMetecCHEMM | $1.75B | 49.1% | 59.9 | +99.42% |
| ElektaEKTA.B | $2.27B | 9.2% | — | +1.17% |
| Medacta GroupMOVE | $2.41B | 15.2% | 27.7 | −30.49% |
Same industry or related industries, similar size. Compare Revenio Group with its competitors · Full profile
